Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05215782 · ClinicalTrials.gov registry record
Eye to Brain Connection
A clinical trial of Alzheimer Disease, sponsored by Optina Diagnostics.
- Completed
- Registry status
- 65
- Enrollment target
- 1
- Study location
NCT05215782: Completed study of Alzheimer Disease, sponsored by Optina Diagnostics.
NCT05215782 is a study of Alzheimer Disease that has completed, run by Optina Diagnostics. The registered enrollment target is 65 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05215782, a study of Alzheimer Disease, has completed, sponsored by Optina Diagnostics.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized, non-treatment, observational study designed to discover correlations between retinal imaging and amyloid PET imaging. Subjects will be recruited to the clinical cohort from referring physicians. Subjects may be participants from existing studies and clinical practices
Conditions Studied
Study Locations (1)
Florida
- Ezy medical research - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2023-03-16 |
What the finished NCT05215782 record still lists
NCT05215782 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05215782 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05215782 about?
NCT05215782 is a clinical study titled "Eye to Brain Connection". This is a non-randomized, non-treatment, observational study designed to discover correlations between retinal imaging and amyloid PET imaging. Subjects will be recruited to the clinical cohort from referring physicians. Subjects may be participants from existing studies and clinical practices
What is the current status of trial NCT05215782?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2022-03-14. Estimated completion is 2023-03-16.
What conditions does trial NCT05215782 study?
This clinical trial studies the following conditions: Alzheimer Disease.
Who is sponsoring clinical trial NCT05215782?
This trial is sponsored by Optina Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05215782 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05215782's enrollment target sits among peer trials
65 181st of 306 higher than 124 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI